Opthea Limited to Present at Key November Investor Conferences
Company Announcements

Opthea Limited to Present at Key November Investor Conferences

Opthea Limited (AU:OPT) has released an update.

Opthea Limited, a biopharmaceutical company specializing in retinal disease treatments, announced its participation in upcoming investor conferences this November. The company will discuss its innovative therapies, including its promising Phase 3 trials for sozinibercept, aimed at improving treatments for wet AMD and diabetic macular edema. Investors and stakeholders can catch these updates during the Virtual Bell Potter and Jefferies London Healthcare Conferences.

For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskOpthea to Highlight Promising AMD Therapy at Key Events
TipRanks Australian Auto-Generated NewsdeskOpthea Set to Highlight Innovations at Investor Conferences
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App